Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise...

Bibliografske podrobnosti
Main Authors:	Antepowicz, A, Tan, A, Pringle, A, Hyde, S, Gill, D
Format:	Conference item
Izdano:	Mary Ann Liebert Inc 2016

Podobne knjige/članki

Development of lung and muscle factories to deliver therapeutic monoclonal antibodies
od: Antepowicz, A
Izdano: (2018)

431. Lung antibody factory for passive immunisation against influenza
od: Tan, T, et al.
Izdano: (2016)

Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza
od: Du, Y, et al.
Izdano: (2020)

Antibody gene transfer for prophylaxis of respiratory syncytial virus (RSV) infection
od: Antepowicz, A, et al.
Izdano: (2018)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
od: Paul-Smith, M, et al.
Izdano: (2017)

Development of monoclonal antibody therapeutics for alzheimer's disease
od: Masatoshi Takeda
Izdano: (2022-01-01)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
od: Paul-Smith, M, et al.
Izdano: (2018)

Monoclonal Antibodies as Neurological Therapeutics
od: Panagiotis Gklinos, et al.
Izdano: (2021-01-01)

Therapeutic monoclonal antibody for Sporotrichosis
od: Sandro eAlmeida
Izdano: (2012-11-01)

The development of gene therapy for diseases of the lung.
od: Gill, DR, et al.
Izdano: (2004)

Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections
od: Leonardo F. Ormundo, et al.
Izdano: (2023-10-01)

Advances and challenges in therapeutic monoclonal antibodies drug development
od: Mariana Lopes dos Santos, et al.
Izdano: (2018-11-01)

Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development
od: Rosalynn Molden, et al.
Izdano: (2021-01-01)

Monoclonal antibodies for the therapeutic induction of tolerance.
od: Waldmann, H, et al.
Izdano: (1993)

Therapeutic potential of monovalent monoclonal antibodies.
od: Cobbold, S, et al.
Izdano: (1984)

The pharmacology and therapeutic applications of monoclonal antibodies
od: María Sofía Castelli, et al.
Izdano: (2019-12-01)

Development and validation of an analytical procedure for the determination of residual protein A in active substances of therapeutic monoclonal antibodies
od: E. V. Nozdrina, et al.
Izdano: (2024-03-01)

Therapeutic Monoclonal Antibodies against Cancer: Present and Future
od: Marisa Delgado, et al.
Izdano: (2023-12-01)

Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244
od: Alexander M. Horspool, et al.
Izdano: (2023-04-01)

Development and Characterization of Monoclonal Antibodies for the Detection of Fish Protein
od: Yi-Tien Chen, et al.
Izdano: (2021-10-01)

Corrigendum: Therapeutic potential of monovalent monoclonal antibodies
od: Cobbold, S, et al.
Izdano: (1984)

Therapeutic Uses of Monoclonal Antibodies for COVID-19
od: Tarun Kumar Suvvari
Izdano: (2020-01-01)

Intramuscular rAAV2/8 mediated expression of etanercept in mice with collagen-induced arthritis
od: Habib, O, et al.
Izdano: (2019)

Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery
od: Pringle, I, et al.
Izdano: (2018)

DEVELOPMENT AND PROPERTIES OF NEUTRALIZING MONOCLONAL ANTIBODIES FOR FUSION PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
od: A. A. Kushch, et al.
Izdano: (2019-04-01)

Therapeutic potential of monoclonal antibodies to the leucocyte common antigen.
od: Bindon, C, et al.
Izdano: (1985)

Identification and characterisation of candidate monoclonal antibody Ebolavirus therapeutics
od: Donnellan, FR
Izdano: (2021)

Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
od: Alvaro Barrera-Ocampo
Izdano: (2024-07-01)

Therapeutic monoclonal antibodies with a focus on hereditary angioedema
od: Bruce L. Zuraw, et al.
Izdano: (2023-01-01)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
od: Aurélien Haustrate, et al.
Izdano: (2019-06-01)

The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
od: Brian Kelley
Izdano: (2024-12-01)

Binding of omeprazole to protein targets identified by monoclonal antibodies
od: Naw May Pearl Cartee, et al.
Izdano: (2020-01-01)

Developing Monoclonal Antibodies for Immunohistochemistry
od: Jacqueline Cordell
Izdano: (2022-01-01)

Impact of Urea on Monoclonal Antibodies: Multiple Destabilization and Aggregation Effects for Therapeutic Immunoglobulin G Proteins
od: Ji Young Yang, et al.
Izdano: (2024-01-01)

Monoclonal antibody techniques. 50 years of development
od: Yulia S. Massino, et al.
Izdano: (2024-07-01)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
od: Liming Liu
Izdano: (2017-04-01)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
od: Antepowicz, A, et al.
Izdano: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
od: C Ian Mockridge, et al.
Izdano: (2022-01-01)

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
od: Isaacs, J, et al.
Izdano: (1992)

Monoclonal antibodies: a review of therapeutic applications and future prospects
od: Mahmuda, Aliyu, et al.
Izdano: (2017)